About KRI Capital
KRI Capital is investing across the entire spectrum of healthcare. We deploy deep clinical and investing experience, leverage our platform of tech-enabled research, and collaborate with industry leaders, partners, and advisors to discover transformative healthcare opportunities. Our main fund supports public companies.
Rakesh Marwah, MD
CEO, Portfolio Manager, & Founder
​
Rakesh Marwah, MD, is the CEO, Portfolio Manager, & Founder of KRI Capital. He brings 20+ years of healthcare investing expertise alongside 25+ years of medical and industry experience.
Before KRI, Dr. Marwah spent nearly 20 years at Palo Alto Investors, advancing from research associate to investment professional. In parallel, he served as Clinical Faculty at Stanford University Medical Center for almost 15 years and, since 2022, as Adjunct Assistant Professor at UT Southwestern Medical Center. Earlier in his career, he led start-up and product-development engagements across the spectrum of healthcare as a consultant.
At Palo Alto Investors, he co-led investments such as Onyx (acquired by Amgen), Auxilium (acquired by Endo), Abiomed (acquired by Johnson & Johnson), Immunomedics (acquired by Gilead), and Provention Bio (acquired by Sanofi), and others. Alongside this medical experience, he leverages his investing expertise and network to source and diligence ideas, engage with management teams and KOLs, drive investment execution and portfolio construction.
Dr. Marwah earned a BS in Biology and an MD from the University of California, Irvine, and completed residency at Stanford University Medical Center. He is a board-certified anesthesiologist.